1
|
Lobo-Martins S, Martins M, Semedo P, Alvim C, Pais HL, Paiva R, Pinto C, Ribeiro L, Fernandes I, Macedo D, Mansinho A, Vendrell I, Sousa RTD, Costa L. P-151 The impact of adjuvant chemotherapy regimens in stage II colon cancer (CC) patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
2
|
Liu L, Garbutt C, Golkaram M, Kaplan S, Martins M, Casino S, Mansinho A, Macedo D, Alvim C, Costa A, Fernandes A, Ferreira C, Aldeia F, Quintela A, Costa L, So A, Zhang S, Pawlowski T. Microsatellite instability testing and lynch syndrome screening for colorectal cancer patients through tumour sequencing. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz257.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
3
|
Gamarra S, Chaves M, Cabeza M, Macedo D, Leonardelli F, Franco D, Boleas M, Garcia-Effron G. Mucormycosis outbreak due to Rhizopus microsporus after arthroscopic anterior cruciate ligament reconstruction surgery evaluated by RAPD and MALDI-TOF Mass spectrometry. J Mycol Med 2018; 28:617-622. [DOI: 10.1016/j.mycmed.2018.09.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 07/06/2018] [Accepted: 09/04/2018] [Indexed: 12/20/2022]
|
4
|
Mansinho A, Ferreira A, Casimiro S, Alho I, Vendrell I, Costa A, Sousa R, Abreu C, Pulido C, Macedo D, Pacheco T, Correia L, Costa L. Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Theill L, Frola C, Leonardelli F, Guelfand L, Macedo D, Cabeza M, Dudiuk C, Garcia-Effron G, Gamarra M. No correlation between fluconazole and voriconazole MIC values and disk inhibition zones diameters in clinical Cryptococcus neoformans strains. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.4044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
6
|
Macedo D, Leonardelli F, Gamarra S, Garcia-Effron G. Rhizopus oryzae intrinsic reduced voriconazole susceptibility is due to Cyp51Ap. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.4071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Ferreira A, Bettencourt M, Alho I, Costa A, Sousa A, Mansinho A, Abreu C, Pulido C, Macedo D, Vendrell I, Pacheco T, Costa L, Casimiro S. Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases. J Bone Oncol 2017; 6:16-21. [PMID: 28194325 PMCID: PMC5294742 DOI: 10.1016/j.jbo.2017.01.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 01/26/2017] [Indexed: 12/19/2022] Open
Abstract
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein level was associated with poor prognosis in several types of cancers, including breast cancer (BC), where it is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen; however the pathological implications of the secreted form of YB-1 (sYB-1) are unknown. Our purpose was to retrospectively evaluate the association between YB-1 measured by ELISA in serum and disease characteristics and outcomes in patients with BC and bone metastases (BM). In our cohort, sYB-1 was detected in the serum of 22 (50%) patients, and was associated with the presence of extra-bone metastases (p=0.044). Positive sYB-1 was also associated with faster bone disease progression (HR 3.1, 95% CI 1.09–8.95, P=0.033), but no significant differences were observed concerning OS, and time to development of skeletal-related events. Moreover, patients with positive sYB-1 also had higher levels of IL-6, a known osteoclastogenic inducer. Therefore, detection of sYB-1 in patients with BC and BM may indicate a higher tumor burden, in bone and extra-bone locations, and is a biomarker of faster bone disease progression.
Collapse
Key Words
- BC, breast cancer
- BM, bone metastases
- BPs, bisphosphonates
- Bone metastases
- Breast cancer
- CSD, cold shock domain
- CT, computed tomography
- CTCs, circulating tumor cells
- CV, coefficient of variation
- EMT, epithelial-to-mesenchymal transition
- HCC, hepatocellular carcinoma
- IL-6, interleukin 6
- IQR, interquartile range
- LPS, lipopolysaccharide
- NTX, N-terminal telopeptide
- OS, overall survival
- Prognostic factor
- SREs, skeletal related events
- Serum biomarker
- TAMs, tumor-associated macrophages
- TTBP, time to bone progression
- TTSRE, time to first skeletal-related event;
- Y-box binding protein 1
- YB-1, Y-box binding protein 1
- sYB-1, secreted/serum YB-1
Collapse
Affiliation(s)
- A.R. Ferreira
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - M. Bettencourt
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - I. Alho
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - A.L. Costa
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - A.R. Sousa
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - A. Mansinho
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - C. Abreu
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - C. Pulido
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - D. Macedo
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - I. Vendrell
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - T.R. Pacheco
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - L. Costa
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - S. Casimiro
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- Correspondence to: Luis Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
| |
Collapse
|
8
|
Pulido C, Caiado J, Ferreira A, Vendrell I, Costa A, Mendes A, Pedro M, Fernandes N, Pestana L, Almeida P, Pinto C, Quintela A, Ribeiro L, Fernandes I, Filipe P, Sousa R, Abreu C, Macedo D, Barbosa M, Costa L. Analysis of cancer outcomes after desensitization protocols in patients with metastatic disease. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Mansinho A, Macedo D, Fernandes I, Quintela A, Costa L. Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Casimiro S, Ferreira A, Alho I, Melo M, Brás R, Costa AL, Sousa AR, Mansinho A, Abreu C, Pulido C, Macedo D, Pacheco TR, Costa L. Abstract P4-09-06: The prognostic role of RANK single nucleotide polymorphisms in breast cancer patients with bone metastases. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Receptor activator of NF-kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. RANK over-expression in primary BC associates with poor prognosis and metastasis development. In patients with BC, RANK and RANK-ligand (RANKL) single nucleotide polymorphisms (SNPs) have also been associated with BC risk and bone metastasis (BM)-free survival , respectively. Here we analyze the association of five RANK missense SNPs with prognosis of patients with BM from BC.
Methods: Missense RANK SNPs (rs34945627, rs12721431, rs35184120, rs35993683, rs61751992) were genotyped in germline DNA from a retrospective cohort of 76 patients with BM from BC, under bisphosphonates; and a cohort of 80 healthy volunteers (samples from Biobanco-IMM, Lisbon, Portugal). Genotypic allelic frequencies were assessed using TaqMan assays (Applied Biosystems). SNP rs34945627 was analyzed with regard to clinicopathological characteristics, skeletal-related events (SRE), bone progression-free interval (BPFi), and overall survival (OS). Univariate association with clinicopathological characteristics was performed using Fisher's exact test and Wilcoxon rank-sum test; univariate differences between survival rates were tested for significance using the log-rank test, while multivariate analysis for survival was tested using Cox proportional hazards models.
Results: SNP rs34945627 had a minor allele frequency of 11.84% (n=9) in BC patients versus 1.25% (n=1) in healthy individuals, whereas the remaining SNPs had a minor allele frequency of 2.60% (n=2) in BC patients. Therefore, for inferential analysis only SNP rs34945627 was considered. No differences between alleles were observed regarding clinicopathological characteristics, including treatment. Homozygous patients (CC) had increased OS when compared to heterozygous patients (CT) controlling for age at diagnosis, visceral involvement, radiographic pattern of BM and baseline urine NTX (adjusted HR 5.76, 95% CI 2.10-15.81; p<0.001). No association could be seen with regard to SREs (adjusted HR 1.43, 95% CI 0.46-4.46; p=0.54) or BPFi (adjusted HR 0.26, 95% CI 0.06-1.17; p=0.08).
Conclusions: RANK SNP rs34945627 seems to be a marker of poor prognosis in patients with BC and BM. Further studies are required to characterize the biological and clinical significance of this finding.
Citation Format: Casimiro S, Ferreira A, Alho I, Melo M, Brás R, Costa AL, Sousa AR, Mansinho A, Abreu C, Pulido C, Macedo D, Pacheco TR, Costa L. The prognostic role of RANK single nucleotide polymorphisms in breast cancer patients with bone metastases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-06.
Collapse
Affiliation(s)
- S Casimiro
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - A Ferreira
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - I Alho
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - M Melo
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - R Brás
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - AL Costa
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - AR Sousa
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - A Mansinho
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - C Abreu
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - C Pulido
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - D Macedo
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - TR Pacheco
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | - L Costa
- Instituto de Medicina Molecular, Lisboa, Portugal; Hospital de Santa Maria, Oncology Division, Lisboa, Portugal; Faculdade de Medicina de Lisboa, Lisboa, Portugal
| |
Collapse
|
11
|
Macedo D, Mansinho A, Costa A, Fernandes I, Costa L. 3445 Hepatotoxicity and therapeutic response with trabectedin in soft tissue sarcomas. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31918-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Lima EBC, Sousa CNS, Meneses LN, Ximenes NC, Santos Júnior MA, Vasconcelos GS, Lima NBC, Patrocínio MCA, Macedo D, Vasconcelos SMM. Cocos nucifera (L.) (Arecaceae): A phytochemical and pharmacological review. ACTA ACUST UNITED AC 2015; 48:953-64. [PMID: 26292222 PMCID: PMC4671521 DOI: 10.1590/1414-431x20154773] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 04/15/2015] [Indexed: 01/13/2023]
Abstract
Cocos nucifera (L.) (Arecaceae) is commonly called the “coconut
tree” and is the most naturally widespread fruit plant on Earth. Throughout history,
humans have used medicinal plants therapeutically, and minerals, plants, and animals
have traditionally been the main sources of drugs. The constituents of C.
nucifera have some biological effects, such as antihelminthic,
anti-inflammatory, antinociceptive, antioxidant, antifungal, antimicrobial, and
antitumor activities. Our objective in the present study was to review the
phytochemical profile, pharmacological activities, and toxicology of C.
nucifera to guide future preclinical and clinical studies using this
plant. This systematic review consisted of searches performed using scientific
databases such as Scopus, Science Direct, PubMed, SciVerse, and Scientific Electronic
Library Online. Some uses of the plant were partially confirmed by previous studies
demonstrating analgesic, antiarthritic, antibacterial, antipyretic, antihelminthic,
antidiarrheal, and hypoglycemic activities. In addition, other properties such as
antihypertensive, anti-inflammatory, antimicrobial, antioxidant, cardioprotective,
antiseizure, cytotoxicity, hepatoprotective, vasodilation, nephroprotective, and
anti-osteoporosis effects were also reported. Because each part of C.
nucifera has different constituents, the pharmacological effects of the
plant vary according to the part of the plant evaluated.
Collapse
Affiliation(s)
- E B C Lima
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - C N S Sousa
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - L N Meneses
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - N C Ximenes
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - M A Santos Júnior
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - G S Vasconcelos
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - N B C Lima
- Laboratório de Farmacologia, Centro Universitário Christus, Fortaleza, CE, Brasil
| | - M C A Patrocínio
- Laboratório de Farmacologia, Centro Universitário Christus, Fortaleza, CE, Brasil
| | - D Macedo
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - S M M Vasconcelos
- Laboratório de Neuropsicofarmacologia, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| |
Collapse
|
13
|
Neves J, Fernandes I, Ribeiro J, Macedo D, Costa L. The Role of Nephrectomy in Metastatic Renal Cell Carcinoma - A Single Centre Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33452-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
14
|
Braga B, Poyares D, Cintra F, Guilleminault C, Cirenza C, Horbach S, Macedo D, Silva R, Tufik S, De Paola AAV. Sleep-disordered breathing and chronic atrial fibrillation. Sleep Med 2009; 10:212-6. [PMID: 18280206 DOI: 10.1016/j.sleep.2007.12.007] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2007] [Revised: 12/17/2007] [Accepted: 12/19/2007] [Indexed: 12/15/2022]
Abstract
BACKGROUND Little has been known about the prevalence of sleep apnea in patients with atrial fibrillation (AF). Studies have suggested that the prevalence of AF is increasing in patients with sleep-disordered breathing. We hypothesize that the prevalence of OSA is higher in chronic persistent and permanent AF patients than a sub-sample of the general population without this arrhythmic disorder. OBJECTIVE Evaluate the frequency of Obstructive Sleep Apnea in a sample of chronic AF compared to a sub-sample of the general population. METHODS Fifty-two chronic AF patients aged (60.5 +/- 9.5, 33 males) and 32 control (aged 57.3 +/- 9.6, 15 males). All subjects were evaluated by a staff cardiologist for the presence of medical conditions and were referred for polysomnography. The differences between groups were analyzed by ANOVA for continuous variables, and by the Chi-square test for dichotomous variables. Statistical significance was established by alpha=0.05. RESULTS There were no differences in age, gender, BMI, sedentarism, presence of hypertension, type 2 diabetes mellitus, abdominal circumference, systolic and diastolic blood pressure, and sleepiness scoring between groups. Despite similar BMI, AF patients had a higher neck circumference compared to control group (39.9cm versus 37.7cm, p=0.01) and the AF group showed higher percentage time of stage 1 NREM sleep (6.4% versus 3.9%, p=0.03). Considering a cut-off value for AHI >= 10 per hour of sleep, the AF group had a higher frequency of OSA compared to the control group (81.6% versus 60%, p=0.03). All the oxygen saturation parameters were significantly worse in the AF group, which had lower SaO(2) nadir (81.9% versus 85.3%, p=0.01) and mean SaO(2) (93.4% versus 94.3%, p=0.02), and a longer period of time below 90% (26.4min versus 6.7min, p=0.05). CONCLUSION Sleep-disordered breathing is more frequent in chronic persistent and permanent AF patients than in age-matched community dwelling subjects.
Collapse
Affiliation(s)
- B Braga
- Sleep Institute, Psychobiology Department, Universidade Federal de Sao Paulo, Rua Marselhesa 524, Vila Clementino, Sao Paulo, SP, Brazil; Cardiology Section, Universidade Federal de Sao Paulo, Brazil.
| | | | | | | | | | | | | | | | | | | |
Collapse
|